Target Name: DDTL
NCBI ID: G100037417
Review Report on DDTL Target / Biomarker Content of Review Report on DDTL Target / Biomarker
Other Name(s): D-dopachrome decarboxylase-like protein | D-dopachrome tautomerase like | KB-226F1.2 | DDTL_HUMAN | D-dopachrome tautomerase-like protein | Phenylpyruvate tautomerase II | D-dopachrome decarboxylase | DDT

DDTL: A Promising Drug Target and Biomarker


In the field of biomedical research, the identification of drug targets and biomarkers plays a crucial role in the development of effective therapeutic interventions and diagnostic strategies. One such noteworthy drug target and biomarker is DDTL (Dihydrodiol Dehydrogenase-Like). DDTL has gained significant attention due to its involvement in various disease processes and its potential as a therapeutic target. This article aims to explore the multifaceted roles of DDTL, emphasizing its importance as a drug target and biomarker in several pathological conditions.

The Role of DDTL in Disease Processes

DDTL is a member of the short-chain dehydrogenase/reductase (SDR) superfamily of enzymes, which are involved in various physiological and pharmacological processes. In recent years, mounting evidence has highlighted the critical role of DDTL in several disease processes.

1. Cancer:

Several studies have implicated DDTL in the development and progression of cancer. High expression levels of DDTL have been observed in various malignancies, including lung, breast, liver, and prostate cancer. In lung cancer, DDTL has been shown to promote tumor growth by activating signaling pathways that contribute to cell proliferation and survival. Additionally, DDTL has emerged as a potential marker for chemoresistance, as its overexpression has been associated with resistance to certain anticancer drugs.

2. Neurological Disorders:

DDTL has also been implicated in various neurological disorders. In Alzheimer's disease (AD), DDTL levels are significantly elevated in the brains of affected individuals. Its upregulation correlates with the accumulation of amyloid-beta plaques, a hallmark of AD pathogenesis. Moreover, DDTL has been shown to enhance neuroinflammation and neuronal oxidative stress, contributing to neurodegenerative processes.

3. Diabetes and Metabolic Disorders:

Studies have demonstrated the involvement of DDTL in the development of diabetes and metabolic disorders. In both type 1 and type 2 diabetes, DDTL expression is heightened in pancreatic beta cells, suggesting its potential role in the impairment of insulin secretion. Furthermore, DDTL has been linked to the regulation of lipid metabolism and adipogenesis, implicating its contribution to obesity and metabolic syndrome.

DDTL as a Drug Target

Given the significant role of DDTL in various disease processes, it has emerged as an attractive target for drug development. Inhibition of DDTL activity or suppression of its expression holds promise for therapeutic interventions.

1. Anticancer Therapies:

In cancer research, targeting DDTL has shown promise as a potential treatment strategy. Inhibition of DDTL enzymatic activity has been effective in reducing tumor growth and sensitizing cancer cells to chemotherapy in preclinical models. Furthermore, DDTL inhibitors have been developed, which demonstrate promising antitumor activity in both in vitro and in vivo studies.

2. Alzheimer's Disease Therapies:

Given its implication in AD pathogenesis, targeting DDTL could have therapeutic potential. In animal models of Alzheimer's disease, the inhibition of DDTL has shown to reduce amyloid-beta plaque accumulation and improve cognitive functions. These findings highlight the potential of DDTL inhibitors as a novel approach for AD treatment.

3. Diabetes and Metabolic Disorder Therapies:

DDTL inhibition has also been investigated as a potential therapeutic approach for diabetes and metabolic disorders. In animal models, DDTL suppression leads to improved glucose homeostasis and increased insulin secretion in response to glucose. This suggests that DDTL inhibitors could be beneficial in managing insulin resistance and obesity-related metabolic dysfunctions.

The Potential of DDTL as a Biomarker

Apart from its role as a drug target, DDTL also holds promise as a biomarker for various diseases. Its unique expression patterns in different pathologies make it a potential diagnostic and prognostic indicator.

1. Cancer Biomarker:

DDTL has shown promise as a biomarker in cancer diagnosis and prognosis. Elevated DDTL expression has been correlated with poor overall survival and disease progression in several cancer types. Therefore, measuring DDTL levels could aid in early cancer detection, prognosis assessment, and treatment stratification.

2. Neurological Biomarker:

DDTL levels in cerebrospinal fluid and blood have been associated with neurodegenerative disorders like AD. Its measurement has the potential to serve as a non-invasive biomarker for early AD detection and disease monitoring. Moreover, DDTL expression levels could potentially predict the response to certain AD therapies.

3. Metabolic Biomarker:

In metabolic disorders, such as diabetes and obesity, DDTL expression correlates with disease severity and progression. Monitoring DDTL levels could provide valuable information for disease management, treatment evaluation, and risk assessment.


DDTL, a versatile player in disease processes, has emerged as both a compelling drug target and an informative biomarker. Its involvement in cancer, neurological disorders, and metabolic disorders highlights its potential clinical significance. Moreover, therapeutic interventions targeting DDTL and its use as a biomarker hold promise for improved diagnostics and personalized treatment strategies. Further research and clinical trials are warranted to fully explore the therapeutic potential and diagnostic utility of DDTL in diverse pathological conditions.

Protein Name: D-dopachrome Tautomerase Like

Functions: May have lyase activity

The "DDTL Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about DDTL comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at

More Common Targets

DDX1 | DDX10 | DDX11 | DDX11-AS1 | DDX11L1 | DDX11L10 | DDX11L2 | DDX11L8 | DDX11L9 | DDX12P | DDX17 | DDX18 | DDX18P1 | DDX19A | DDX19A-DT | DDX19B | DDX20 | DDX21 | DDX23 | DDX24 | DDX25 | DDX27 | DDX28 | DDX31 | DDX39A | DDX39B | DDX39B-AS1 | DDX3P1 | DDX3X | DDX3Y | DDX4 | DDX41 | DDX42 | DDX43 | DDX46 | DDX47 | DDX49 | DDX5 | DDX50 | DDX50P1 | DDX51 | DDX52 | DDX53 | DDX54 | DDX55 | DDX56 | DDX59 | DDX59-AS1 | DDX6 | DDX60 | DDX60L | DDX6P1 | DEAF1 | Death-associated protein kinase | Decapping Complex | DECR1 | DECR2 | DEDD | DEDD2 | Dedicator of cytokinesis protein | DEF6 | DEF8 | DEFA1 | DEFA10P | DEFA11P | DEFA1B | DEFA3 | DEFA4 | DEFA5 | DEFA6 | DEFA7P | DEFA8P | DEFA9P | DEFB1 | DEFB103A | DEFB103B | DEFB104A | DEFB104B | DEFB105A | DEFB105B | DEFB106A | DEFB106B | DEFB107A | DEFB108B | DEFB108F | DEFB109A | DEFB109B | DEFB109C | DEFB110 | DEFB112 | DEFB113 | DEFB114 | DEFB115 | DEFB116 | DEFB118 | DEFB119 | DEFB121 | DEFB122 | DEFB123 | DEFB124